Artificial cells

• US 20110070154A1
• Filed: 08/03/2010
• Published: 03/24/2011
• Est. Priority Date: 08/13/2008
• Status: Abandoned Application

• Current Assignee: Searete LLC (Intellectual Ventures LLC)
• Original Assignee: Searete LLC (Intellectual Ventures LLC)
• Inventors: McKnight, Gary L., Ishikawa, Muriel Y., Kindsvogel, Wayne R., Wood, Lowell L. JR., Hyde, Roderick A., Sweeney, Elizabeth A.
• Application Number:
  US12/806,007
• Publication Number:
  US 20110070154A1
• Time in Patent Office: Days
• US Class Current: 424/1.17
• CPC Class Codes: A61K 2039/515 Animal cells
• CPC Class Codes: A61K 2039/5154 Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
• CPC Class Codes: A61K 2039/5156 expressing foreign proteins
• CPC Class Codes: A61K 2039/55516 Proteins; Peptides
• CPC Class Codes: A61K 2039/55555 Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
• CPC Class Codes: A61K 2039/605 MHC molecules or ligands thereof
• CPC Class Codes: A61K 35/18 Erythrocytes haemoglobin A61K38/42
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 41/0071 PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
• CPC Class Codes: A61K 47/6901 Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
• CPC Class Codes: A61K 49/0002 General or multifunctional contrast agents, e.g. chelated agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: C12N 5/0006 Modification of the membrane of cells, e.g. cell decoration
• CPC Class Codes: C12N 5/0641 Erythrocytes

Abstract

The present disclosure relates to various embodiments associated with artificial cells, particularly artificial antigen presenting cells, methods of making the same, methods of administering the same, computer systems relating thereto, computer-implemented methods relating thereto, and associated computer program products.

Claims

1. A composition, comprising:

a lipid surface including at least one artificial antigen presenting cell complex, the artificial antigen presenting cell complex including at least one epitope joined to at least one MHC receptor component, and at least one immunomodulatory molecule component joined to the at least one MHC receptor component.

2. The composition of claim 1, wherein the at least one immunomodulatory molecule component joined to the at least one MHC receptor component is joined by at least one linker or linking component.

3. The composition of claim 2, wherein the at least one linker includes at least one cleavable linker.

21. The composition of claim 1, wherein the lipid surface includes at least a portion of at least one of a liposome, lipid droplet, chemical emulsion, phase separation, exosome, micelle, platelet, chip, device, cell, cerasome, lipid monolayer, lipid bilayer, lipid multilayer, or red blood cell ghost.

23. The composition of claim 21, wherein the cell further includes at least one death-initating component.

24. The composition of claim 23, wherein the at least one cell death-initiating component includes at least one cell death-initiating nucleic acid construct.

25. The composition of claim 24, wherein the at least one cell death-initiating nucleic acid construct includes at least one inducible regulatory element.

26. The composition of claim 24, wherein the at least one cell death-initiating nucleic acid construct encodes at least one gene product sufficient to initiate death of the modified cell.

27. The composition of claim 24, wherein the at least one cell death-initiating nucleic acid construct is configured to initiate programmed cell death of the cell.

28. The composition of claim 24, wherein the at least one cell death-initiating nucleic acid construct is configured to initiate at least one of necrosis, pyroptosis, autophagocytosis, or apoptosis of the cell.

29. The composition of claim 24, wherein the at least one cell death-initiating nucleic acid construct encodes at least one programmed cell death gene product.

38. The composition of claim 1, wherein the MHC receptor component includes at least a portion of one or more of a Major Histocompatibility Class I protein, Major Histocompatibility Class II protein, or Major Histocompatibility Class III protein.

39. The composition of claim 1, wherein the at least one MHC receptor component includes at least a portion of one or more of β

-2 microglobulin, Transporter Associated with Antigen Processing (TAP), MHC class I α

-1 domain, MHC class I α

-2 domain, MHC class I α

-3 domain, tapasin, calreticulum, ERP57, or calnexin.

41. The composition of claim 1, wherein the at least one MHC receptor component includes at least a portion of one or more of a MHC class II α

domain, or a β

domain.

42. The composition of claim 41, wherein the at least a portion of the MHC class II α

domain includes at least a portion of one or more of α

-1 domain or α

-2 domain.

43. The composition of claim 41, wherein the at least a portion of the β

domain includes at least a portion one of one or more of β

-1 domain or β

-2 domain.

44. The composition of claim 1, wherein the at least one MHC receptor component encodes at least one gene product of one or more of HLA-A, HLA-B, HLA-C, HLA-DPA1, HLA-DPB1, HLA-DRA, HLA-DRB1, HLA-DQA1, or HLA-DQB1 genes.

45. The composition of claim 1, further comprising at least one therapeutic agent.

52. The composition of claim 45, wherein the at least one therapeutic agent includes at least one vaccine.

53. The composition of claim 52, wherein the at least one vaccine includes at least one of an antigenic peptide, antigenic protein, or antigenic carbohydrate.

54. The composition of claim 52, wherein the at least one vaccine includes at least one of an envelope protein, capsid protein, surface protein, toxin, polysaccharide, or oligosaccharide.

55. The composition of claim 52, further comprising at least one adjuvant.

56. The composition of claim 45, wherein the at least one therapeutic agent includes at least one cytokine.

60. The composition of claim 45, wherein the at least one therapeutic agent includes at least one prodrug or precursor compound.

61. The composition of claim 60, wherein the at least one prodrug or precursor compound includes at least one glucuronide prodrug.

62. The composition of claim 61, wherein the at least one glucuronide prodrug includes at least one glucuronide of epirubicin, 5-fluorouracil, 4-hydroxycyclophosphamide, or 5-fluorocytosine.

63. The composition of claim 61, wherein the at least one prodrug or precursor compound includes 5-(aziridin-1-yl)-2,4-dinitrobenzamide.

64. The composition of claim 45, wherein the at least one therapeutic agent includes at least one converting enzyme active with the at least one prodrug or precursor compound.

65. The composition of claim 64, wherein the at least one enzyme includes at least one of β

glucuronidase or cytosine deaminase.

66. The composition of claim 64, wherein the at least one enzyme includes nitroreductase or nitroreductase-like compound.

67. The composition of claim 45, wherein the at least one therapeutic agent includes at least a portion of an antibody expressed on the surface of the artificial antigen presenting cell.

72. The composition of claim 1, further comprising at least one nanoparticle.

73. The composition of claim 72, wherein the at least one nanoparticle includes at least one taggant, contrast agent, sensor, semiconductor, or electronic identification device.

78. The composition of claim 1, further comprising at least one radioactive, luminescent, colorimetric, or odorous substance.

79. The composition of claim 1, further comprising at least one photoactivatable molecule.

80. The composition of claim 79, wherein the at least one photoactivatable molecule includes psoralen.

84. The composition of claim 1, wherein the at least one MHC receptor component is customized for at least one subject or at least one group of subjects.

85. The composition of claim 84, wherein the at least one MHC receptor component shares at least one allele with the subject'"'"'s endogenous MHC.

89. The composition of claim 1, wherein at least two of the components of the antigen presenting cell complex are displayed in a pre-determined arrangement.

94. The composition of claim 84, wherein the epitopes include a different genetic variant.

95. The composition of claim 84;

wherein at least one of the two or more antigen presenting cell complexes further includes at least one immunomodulatory molecule joined to the at least one MHC receptor component.

96. The composition of claim 84, wherein at least two of the two or more antigen presenting cell complexes include different immunomodulatory molecues joined to the at least one MHC receptor component.

97. The composition of claim 84, wherein at least two of the two or more antigen presenting cell complexes are different from each other.

4-20. -20. (canceled)

22. (canceled)

30-37. -37. (canceled)

40. (canceled)

46-51. -51. (canceled)

57-59. -59. (canceled)

68-71. -71. (canceled)

74-77. -77. (canceled)

81-83. -83. (canceled)

86-88. -88. (canceled)

90-92. -92. (canceled)

93. A composition, comprising:

a lipid surface including at least one suite of artificial antigen presenting cell complexes, each suite including at least two artificial antigen presenting cell complexes, each artificial antigen presenting cell complex including at least one epitope joined to at least one MHC receptor component, wherein at least two artificial antigen presenting cell complexes include epitopes of different antigens.

98-105. -105. (canceled)

106. A method of modulating an immune response, comprising providing to at least one biological tissue, at least one composition including one or more artificial antigen presenting cells for a time sufficient to modulate an immune response, wherein the at least one artificial antigen presenting cell includes at least one epitope joined to at least one MHC receptor component displayed on at least one of the inner or outer surface of a lipid or polymeric vehicle.

107. The method of claim 106, further comprising at least one immunomodulatory molecule component joined to the at least one MHC receptor component.

108. The method of claim 106, wherein the at least one biological tissue is located in a subject.

111. The method of claim 106, further comprising inducing the at least one artificial antigen presenting cell to dissociate.

134. The method of claim 106, wherein the at least one artificial antigen presenting cell is formulated to modulate at least one immune response.

135. The method of claim 134, wherein the at least one immune response includes at least one of an allergic or autoimmune response.

136. The method of claim 134, wherein the at least one immune response includes at least one lymphocyte response.

137. The method of claim 134, wherein the modulation at least one immune response includes at least one of modulation of immune cell activation, modulation of immune cell anergy, modulation of immune cell antibody production, modulation of immune cell death, modulation of immune cell class or subclass, modulation of immune cell type, or modulation of production of at least one cytokine.

109-110. -110. (canceled)

112-133. -133. (canceled)

138-154. -154. (canceled)